George Magrath
Chief Executive Officer and Board Member at Opus Genetics(formerly Ocuphire Pharma)
Charleston, US
About
George Magrath, MD, is Chief Executive Officer and a Board member of Opus Genetics, a publicly traded biotechnology company that develops medicines and therapies to treat rare genetic diseases causing childhood blindness. Drawing on his extensive clinical research, business, finance, and board experience, in 2023, he led the acquisition of Opus Genetics by Ocuphire Pharma, spearheading the merger and integration of both companies' assets and staff. Noted for establishing a predictive AI model to help identify which patients are most likely to benefit from the groundbreaking treatments Opus Genetics is developing, he’s also pioneering an AI tool designed for clinical trial management to reduce costs to encourage more biotech companies to develop cures for orphan diseases. He previously served as Chief Medical Officer and then CEO of Lexitas Pharmaceuticals Services, Inc., a contract provider of clinical trials, regulatory, and medical strategy services to pharmaceutical and biotechno
Position in the VCSift Database
- • 8 investors hold the Chief Executive Officer and Board Member role in VCSift. George Magrath is one of them.
- • 110 investors are based in Charleston, South Carolina, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Charleston, US
Contact Information
Find more investors like George
Search Investors